LiliumX develops and uses an assembly platform which combines known protein and antibody components into bispecifics, then tests them for improved or novel drug candidates. Traditional antibodies bind to a single cellular target, but bispecifics can bring together and bind to two unique targets, which can, for example, kill cancer cells. LiliumX’s platform enables the rapid screening of bispecific drug candidates with complex designs or modifications, which are not feasible with current bispecific technologies.